TNFSF13 Antikörper

Produktnummer ABIN2664055

Dieser Anti-TNFSF13 Antikörper ist ein Maus Monoklonal Antikörper zur Detektion von TNFSF13 in FACS. Geeignet für Human.

Kurzübersicht für TNFSF13 Antikörper (ABIN2664055)

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFSF13 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: 33H5

Produktdetails anti-TNFSF13 Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TNFSF13

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Andere Bezeichnung: APRIL TNFSF13

Hintergrund: APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, stimulates cell proliferation. It is a member of the TNF superfamily of ligands, being most closely related to BAFF, with which it shares 30 % amino acid sequence identity. APRIL is cleaved intracellularly by furin and is believed to exist mainly in a secreted, soluble form. As with most other TNF family members, APRIL exists as a functional homotrimer (total MW = 90 kD). It can bind to two cell-surface receptors: BCMA and TACI, which it shares with BAFF, to exert downstream T- and B-cell regulatory effects. It also possesses a heparin binding domain and has been demonstrated to bind to proteoglycans on the cell surface. APRIL is most well known for its tumor proliferation effects. It is a potential biomarker, with serum levels elevated for certain cancers and expression levels elevated in cancer tissues. It is also a potential biomarker for certain autoimmune diseases. In fact, recombinant TACI has been brought to clinical trials as a neutralization drug against APRIL and BAFF for the treatment of systemic lupus erythematosus (SLE). Besides forming homotrimers, APRIL can also form functional heterotrimers with BAFF. The stoichiometric relationship of the protomeric units is still unclear, however, it appears that these heterotrimers are significant in that they are elevated in the serum of certain autoimmune patients. APRIL also forms an endogenous chimeric protein with another related protein, TWEAK, effectively called TWE-PRIL. It is believed that TWE-PRIL is membrane bound, and consists of the N-terminus of TWEAK with its transmembrane domain, and the C-terminus of APRIL with its receptor binding domain.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response